Mobile

An Open Label Extension Study Evaluating the Safety of Long Term Dosing of Romiplostim in Thrombocytopenic Subjects with Myelodysplastic Syndromes (MDS)

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-001516-24

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective is to provide long-term safety data for the use of romiplostim in thrombocytopenic subjects with myelodysplastic syndromes (MDS).

Critère d'inclusion

  • Thrombocytopenic Subjects with Myelodysplastic Syndrome (MDS)

Liens